Ascletis Pharma Inc. has announced the development of ASC30, an investigational GLP-1R biased small molecule agonist designed for both oral and subcutaneous administration. In a U.S. Phase Ib clinical study, ASC30's ultra-long-acting subcutaneous depot formulation demonstrated an observed half-life of 75 days in participants with obesity, supporting once-quarterly administration as a maintenance therapy for chronic weight management. Additionally, the ASC30 treatment formulation has shown an observed half-life of 46 days, indicating potential for once-monthly administration. Topline data from the Phase IIa study for ASC30 treatment formulation are expected in the first quarter of 2026. The company holds patent protection for ASC30, a new chemical entity, until 2044.